Abstract
Understanding the rapid epidemic growth of the novel SARS-CoV-2 Omicron variant is critical for public health management. We compared the secondary attack rate (SAR) of the Omicron and Delta variants in households using Norwegian contact tracing data from December 2021 to January 2022. Omicron SAR was higher (51%) than Delta (36%), with a relative risk (RR) of 1.41 (95% CI 1.27-1.56). We observed increased susceptibility to Omicron infection in household contacts compared to Delta independent of vaccination status; however, considering booster vaccinated contacts, the mean SAR was lower for both variants. We found increased Omicron transmissibility in all vaccination groups of primary cases, except partially vaccinated, compared to Delta. In particular, Omicron SAR for boosted primary cases was high, 46% vs 11 % for Delta (RR 4.34; 95% CI 1.52-25.16). In conclusion, booster doses decrease the infection risk of Delta and Omicron but have limited effect in preventing Omicron transmission.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The study was funded by the Norwegian Institute of Public Health (NIPH), and the Norwegian Research Council (grant 312721) and the Nordic Research Council (grant 105572).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The studies uses data from the Norwegian emergency registry Beredt C19. We have ethics approval for the use of data in this article, authorized through the Norwegian Health Preparedness Act, paragraphs 2-4, more information is available at https://www.fhi.no/en/id/infectious-diseases/coronavirus/emergency-preparedness-register-for-covid-19/. In addition, we have obtained ethics approval for the use of data from the Regional Committees for Medical and Health Research Ethics South-East in Norway (REK), project number 400038, see: https://app.cristin.no/projects/show.jsf?id=2526974
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Updated manuscript based on updated data;
Data Availability
The complete data set referred to in this manuscript is not publicly available as it contains person sensitive information. The Norwegian Institute of Public Health is data controller for the emergency preparedness registry BERECT-C19. The registry is temporary, and there are strict access control and routines for information handling information in the registry. Individual requests for access to non-sensitive data can be made to the Norwegian Institute of Public Health.
